Literature DB >> 16264989

Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer.

Eric B Haura1, James Turkson, Richard Jove.   

Abstract

Members of the signal transducers and activators of transcription (STAT) pathway, which were originally identified as key components linking cytokine signals to transcriptional events in cells, have recently been demonstrated to have a major role in cancer. They are cytoplasmic proteins that form functional dimers with each other when activated by tyrosine phosphorylation. Activated STAT proteins translocate to the nucleus to regulate expression of genes by binding to specific elements within gene promoters. Constitutive activation of the STAT family members Stat3 and Stat5, and/or loss of Stat1 signaling, is found in a large group of diverse tumors. Increasing evidence demonstrates that STAT proteins can regulate many pathways important in oncogenesis including cell-cycle progression, apoptosis, tumor angiogenesis, tumor-cell invasion and metastasis, and tumor-cell evasion of the immune system. Based on these findings, a growing effort is underway to target STAT proteins directly and indirectly for cancer therapy. This review will highlight STAT signaling pathways, STAT target genes involved in cancer, evidence for STAT activation in human cancers, and therapeutic strategies to target STAT molecules for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264989     DOI: 10.1038/ncponc0195

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  156 in total

1.  Absolute requirement for STAT3 function in small-intestine crypt stem cell survival.

Authors:  J R Matthews; O J Sansom; A R Clarke
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

2.  JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma.

Authors:  Zhenbing You; Dafu Xu; Jian Ji; Wei Guo; Weiguo Zhu; Jingdong He
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 3.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

4.  Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.

Authors:  Shuo Wang; Christos Patsis; Antonis E Koromilas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

Review 5.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Authors:  Jinah Park; Junil Kim; Bora Park; Kyung-Min Yang; Eun Jin Sun; Cristina E Tognon; Poul H Sorensen; Seong-Jin Kim
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

7.  Constitutively active STAT6 predisposes toward a lymphoproliferative disorder.

Authors:  Mark H Kaplan; Sarita Sehra; Hua-Chen Chang; John T O'Malley; Anubhav N Mathur; Heather A Bruns
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

Review 8.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 9.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.